NCT06923176View on ClinicalTrials.gov

Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

704

Participants

Timeline

Start Date

April 19, 2025

Primary Completion Date

April 30, 2031

Study Completion Date

April 30, 2031

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Biejia-Ruangan compound

Biejia-Ruangan compound have the functions of softening hardness, dispersing lumps, removing blood stasis and detoxifying, and nourishing qi and blood. Used for chronic hepatitis B liver fibrosis, as well as early liver cirrhosis characterized by blood stasis obstructing collaterals, qi and blood deficiency with incomplete heat toxicity.

OTHER

Routine medical care

Routine medical care

All Listed Sponsors
lead

Zhiyun Yang

OTHER